Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2020
NICE backs Portola's Ondexxya
11 September 2020 - NICE has published the outcome of an appraisal consultation document backing NHS funds for restricted use ...
Posted by Michael Wonder on 11 Sep 2020
Nasal spray medicine for treatment-resistant depression not recommended by NICE
3 September 2020 - Consultation open on draft guidance until Friday 25 September 2020. ...
Posted by Michael Wonder on 09 Sep 2020
Another appraisal terminated by NICE
9 September 2020 - That makes it 9 terminated appraisals so this calendar year. ...
Posted by Michael Wonder on 08 Sep 2020
NICE releases initial guidance for another indication for lenalidomide
8 September 2020 - This time, it is for use as maintenance treatment after autologous stem cell transplantation for patients ...
Posted by Michael Wonder on 07 Sep 2020
AstraZeneca vaccine ‘most likely’ to roll out in the U.K. early next year
7 September 2020 - Rise in U.K. COVID cases is predominantly among younger people, health secretary says. ...
Posted by Michael Wonder on 06 Sep 2020
NICE not supportive of encorafenib for metastatic colorectal cancer
4 September 2020 - NICE has responded to the request of the Department of Health and Social Care to produce ...
Posted by Michael Wonder on 05 Sep 2020
Real world evidence to support payer/HTA decisions about highly innovative technologies in the EU—actions for stakeholders
3 September 2020 - There are divergent views on the potential of real world data to inform decisions made by regulators, ...
Posted by Michael Wonder on 03 Sep 2020
Janssen disappointed with second NICE no for Spravato
3 September 2020 - Janssen says it is disappointed with second draft guidance from the National Institute for Health and ...
Posted by Michael Wonder on 02 Sep 2020
NICE terminates yet another assessment of a new cancer medicine
2 September 2020 - This time it is a new medicine for patients with acute myeloid leukaemia. ...
Posted by Michael Wonder on 02 Sep 2020
NICE unable to assess new indication for Soliris
2 September 2020 - NICE was hopeful of being able to assess eculizumab for the treatment of patients with relapsing ...
Posted by Michael Wonder on 02 Sep 2020
Novo launches type 2 diabetes pill in UK after NICE waives review
1 September 2020 - Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost ...
Posted by Michael Wonder on 02 Sep 2020
NICE green light for immunotherapy Bavencio
2 September 2020 - NICE has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) ...
Posted by Michael Wonder on 28 Aug 2020
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
28 August 2020 - MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as ...
Posted by Michael Wonder on 25 Aug 2020
Recruitment begins to fill up to seven non-executive roles on the NICE board
25 August 2020 - Roles will contribute to the development of the NICE’s strategic objectives. ...
Posted by Michael Wonder on 22 Aug 2020
NHS cannabis guidelines challenged in court
18 August 2020 - The parents of a three-year-old boy with severe epilepsy are going to court to mount the ...